今天FDA批准了Xolremdi 用于治疗WHIM syndrome:CXCR4 antagonist
版主: Tlexander
-
- 论坛点评
- 帖子: 3056
- 注册时间: 2022年 7月 22日 17:34
#1 今天FDA批准了Xolremdi 用于治疗WHIM syndrome:CXCR4 antagonist
今天FDA批准了Xolremdi 用于治疗WHIM syndrome。我看到大家都没讨论,提醒一下。Xolremdi (mavorixafor) is a CXCR4 antagonist, and its mechanism of action is based on blocking the dysregulated CXCR4 receptor that causes WHIM syndrome. It binds to and blocks the CXCR4 chemokine receptor, preventing it from being activated by its natural ligand CXCL12 (also called SDF-1)